Navigation Links
Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition
Date:5/23/2013

TUCSON, Ariz., May 23, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the Glasgow Science Centre in Scotland, which boasts more than 380,000 visitors annually, is featuring the SynCardia temporary Total Artificial Heart powered by the Freedom® portable driver as part of its $3 million Bodyworks Exhibition, one of the most advanced exhibitions of its kind.

(Photo: http://photos.prnewswire.com/prnh/20130523/LA19649)

"BodyWorks combines the latest technology with an excellent approach to story-telling to define and explain that most complex of entities, the human body," said Dr. Stephen Breslin , chief executive of Glasgow Science Centre.

The "Heart Pod" featuring the SynCardia Total Artificial Heart powered by the Freedom portable driver is one of 115 interactive exhibits, research capsules and live laboratory experiences that explore the science of health and wellbeing in the 21st Century. In order to demonstrate the innovative engineering behind this life-saving technology, the museum fabricated a full-size, semi-transparent human torso, which includes the skeletal system and internal organs.

Other exhibits for adults and children include:

  • A virtual autopsy table, the only one of its kind in the United Kingdom
  • A giant "hamster wheel" which measures stamina
  • A "DNA disco" that explains genetic science in an entertaining way
  • Plastinated human tissue samples that explain the make-up of the body

The Centre, which is the biggest of its kind outside London, is an award-winning, independent educational charity. Last year, more than 477,000 people experienced the museum's exhibits, with more than 388,892 admissions to the Centre itself, and another 88,141 people reached via programming brought directly to local schools and communities.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – @SynCardia - http://twitter.com/SynCardia
Connect with SynCardia on LinkedIn - http://www.linkedin.com/company/syncardia-systems-inc.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
2. Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures
3. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
4. Sony Delivers New Technology for Science to CYTO 2013
5. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
6. Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd
7. Amgen To Present At The UBS Global Life Sciences Conference
8. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
9. Moving Beyond the Pill: Data Science to Impact Medicine More than the Drugs Themselves
10. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
11. Canadas Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):